



525 Rec'd O/T/PTC 27 JUN 2002 PCT

PATENT
Customer No. 22,852
Attorney Docket No. 3715.0102

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Elisabeth TOURNIER-LASERVE) Group Art Unit: 1648
Application No.: 10/019,434) Examiner: Not assigned
Filed: May 7, 2002)
For: USE OF THE KRIT1 GENE IN)
THE FIELD OF ANGIOGENESIS)

RECEIVED

JUL 1 6 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
Washington, DC 20231

OFFICE OF INITIAL PATENT EXAMINATION

Sir:

REQUEST FOR CORRECTED FILING RECEIPT


We are forwarding herewith a copy of a Filing Receipt for the above-identified patent application. The errors are found in the first name of the first inventor, the third named inventor was omitted, and in the title, the word "kritis" should read --KRIT1--. All of the corrections are shown in ink on the attached copy.

It is respectfully requested that a corrected Filing Receipt be issued as soon as possible.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 27, 2002

By: 
Kenneth J. Meyers
Reg. No. 25,146



UNITED STATES PATENT AND TRADEMARK OFFICE

KJM/USD

COMMISSIONER FOR PATENTS

UNITED STATES PATENT AND TRADEMARK OFFICE

WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/019,434	05/07/2002	1642	1648	03715.0102	3	25	5

RECEIVED

CONFIRMATION NO. 4231

FILING RECEIPT



OC000000008216204

FINNEGAN, HENDERSON,
FARABOW, GARRETT & DUNNER, LLP.

Date Mailed: 06/06/2002

Finnegan Herderson Farabow Garrett & Dunner
 1300 I Street NW
 Washington, DC 20005

JUN 17 2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) *Elisabeth*

Elizabeth Tournier-Lasserve, Paris, FRANCE;
 Sophie Laberge-Le-Couteulx, Rouen, FRANCE;
Pierre Labauge, montpellier, FRANCE

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/FR00/01887 07/03/2000

Foreign Applications

FRANCE 99/08504 07/01/1999

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

Title

KRIT1

Use of the kriti gene in the field of angiogenesis

Preliminary Class

435

Rkt 06/17/02
AS

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).